Limitations, agreements, and source contact

A Study to Compare Tivozanib Hydrochloride to Sorafenib in Participants With Refractory Advanced Renal Cell Carcinoma (RCC) · Source last updated 2023-07-18

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement

pi Sponsor Employee

false

restrictive Agreement

false

point Of Contact

email

Clinical@aveooncology.com

organization

AVEO Pharmaceuticals, Inc.

phone

857-400-0101

title

AVEO Clinical Trial Office

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice